New York, June 4, 2026, 12:04 EDT
- Recursion shares climbed about 12% near midday, outpacing a stronger biotech tape.
- The stock move comes before Recursion’s June 9 appearance at Goldman Sachs’ healthcare conference.
- Recent filings showed small Rule 144 insider-sale notices, while investors remain focused on pipeline and cash-runway updates.
Recursion Pharmaceuticals shares jumped on Thursday, with traders marking up the AI-drug developer before a healthcare conference appearance next week and amid a broader rotation into healthcare stocks.
The Nasdaq-listed stock was recently at $3.87, up 40 cents, after touching $4.03 earlier in the session. Volume was about 24.6 million shares, and the company’s market value stood near $2.05 billion.
Why now is fairly plain. Recursion said this week it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, a venue where investors will be looking for fresh language on clinical timing, cash use and partnerships. The broader artificial-intelligence drug-discovery trade also got a fresh marker Wednesday when Alnylam said it had signed a deal worth up to $2 billion with AI biotech Inceptive to speed discovery of RNA-based medicines.
The move came in a mixed U.S. market. Reuters reported the Dow hit an all-time high while the Nasdaq slipped as chip stocks fell, but healthcare shares rose 3.1%. The iShares Nasdaq Biotechnology ETF, an exchange-traded fund — a basket of shares that trades like a stock — was up about 2.7%, while AI and computational-biology names Tempus AI, Schrödinger and Absci also traded higher.
Recursion calls itself a clinical-stage “TechBio” company, meaning a technology-driven biotechnology firm that has not yet reached the point of selling approved medicines. Its pitch to investors is that large datasets, automated labs and AI models can cut wasted time in drug discovery. Recursion Pharmaceuticals, Inc.
The last full company update came in early May. Recursion said REC-1245, its RBM39 degrader for solid tumors, showed early safety and pharmacokinetic data; pharmacokinetics is how a drug moves through the body. It also said no dose-limiting toxicities had been seen to date, meaning side effects had not yet been severe enough to stop dose escalation.
Chief Executive Najat Khan said then the company was seeing “strong momentum and execution” across its portfolio. The same update showed Recursion had $665.2 million in cash, cash equivalents and restricted cash at March 31 and expected runway into early 2028 without additional financing; cash runway is the period a company expects its funds to cover its plan. Recursion Pharmaceuticals, Inc.
Investors have been especially focused on REC-4881, a drug designed to block MEK1/2 proteins in a cell-growth pathway, for familial adenomatous polyposis, or FAP, an inherited disorder that can cause many gastrointestinal polyps. Recursion said in May it had begun FDA engagement to define a possible registrational study path and expected a regulatory update in the second half of 2026.
Analysts are not uniformly bullish. LSEG data compiled by Capital.com showed a Hold consensus based on eight analysts, with 37.5% at Buy and 62.5% at Hold; the 12-month target range ran from $3 to $11, with an average of $7.
There was also fresh insider-paperwork noise, though small in scale. Recursion’s filing page listed Form 144 notices on June 2 and June 3, and the June 3 notice showed director Namandjé Bumpus proposed selling 4,386 Class A shares with an aggregate market value of about $15,526. Rule 144 is an SEC resale rule for restricted or control securities, often used for planned insider sales.
But the rally can unwind if investors hear little new next week, or if the FDA path for REC-4881 proves slower or less clear than the market wants. Recursion itself has warned it is a clinical-stage biotech with a limited operating history and no products approved by regulators for commercial sale, and its filings flag the need for capital as a core risk.
That leaves Thursday’s move looking less like a single-news spike and more like positioning before a near-term stage appearance. The question for the week ahead is whether management can turn the AI story back into concrete milestones — data, regulatory clarity, or partner payments — before the stock gives back the bid.
